PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-313.81%
Negative net income growth while RVPH stands at 5.90%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
289.12%
SBC growth while RVPH is negative at -56.99%. John Neff would see competitor possibly controlling share issuance more tightly.
-122.10%
Negative yoy working capital usage while RVPH is 125.07%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
113.90%
AP growth well above RVPH's 101.70%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-180.39%
Negative yoy usage while RVPH is 159.63%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
2618.61%
Well above RVPH's 81.82%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
17.02%
Operating cash flow growth below 50% of RVPH's 38.83%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
-23.76%
Negative yoy CapEx while RVPH is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.76%
We reduce yoy invests while RVPH stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-278.89%
We cut debt repayment yoy while RVPH is 52.51%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.